Journal Article Review Epublish
PubMed: 40129984 DOI: 10.3389/fimmu.2025.1505247
A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia.
Front Immunol 16:1505247
Authors: Yaoyao Wang, Xiancong Yang, Yalin Liu, Youjie Li
Affiliations
- Department of Pediatrics of Yantai Affiliated Hospital, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China. Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong, China.
- Laboratory Department, Qilu Hospital of ShanDong University Dezhou Hospital, Dezhou, Shandong, China.
- Department of Pediatrics of Yantai Affiliated Hospital, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China.
- Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong, China.
Abstract
Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients. However, as an emerging therapeutic strategy, immunotherapy has shown great potential in the field of AML treatment in recent years. At present, common immunotherapy methods for AML include monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. With the deepening of research and technological progress, especially the application of nanotechnology in medicine, new immunotherapy is expected to become one of the important means for the treatment of acute myeloid leukemia in the future.
MeSH
Leukemia, Leukemia, Myeloid, Acute, Immunotherapy, Immune Checkpoint Inhibitors, Immune System Diseases, Leukemia, Myeloid, Therapeutics